The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
Open accessAbstract
The role of p53, as a prognostic factor for survival in lung cancer, is controversial and the purpose of the present systematic review of the literature is to determine this effect. Published studies were identified with the objective to aggregate the available survival results after a methodological assessment using a scale specifically designed by the European Lung Cancer Working Party (ELCWP). To be eligible, a study had to deal with p53 assessment in lung cancer (primary site) only, and to provide a survival comparison according to the p53 status. Among the 74 eligible papers, 30 identified p53 abnormalities as a univariate statistically significant poor prognostic factor and 56 provided sufficient data to allow survival results aggregation. There was no significant difference between the trials that either showed or did not show a prognostic effect of p53 according to the methodological score or to the laboratory technique used. The studies were categorized by histology, disease stage, treatment and laboratory technique. Combined hazard ratios suggested that an abnormal p53 status had an unfavourable impact on survival: in any stage nonsmall cell lung cancer (NSCLC) the mean (95% confidence interval) was 1.44 (1.20–1.72) (number of studies included in the subgroup was 11), 1.50 (1.32–1.70) in stages I–II NSCLC (n=19), 1.68 (1.23–2.29) in stages I–IIIB NSCLC (n=5), 1.68 (1.30–2.18) in stages III–IV NSCLC (n=9), 1.48 (1.29–1.70) in surgically resected NSCLC (n=20), 1.37 (1.02–1.85) in squamous cell carcinoma (n=9), 2.24 (1.70–2.95) in adenocarcinoma (n=9), 1.57 (1.28–1.91) for a positive immunohistochemistry with antibody 1801 (n=8), 1.25 (1.09–1.43) for a positive immunohistochemistry with antibody DO-;7 (n=16), and 1.65 (1.35–2.00) for an abnormal molecular biology test (n=13). Data were insufficient to determine the prognostic value of p53 in small cell lung cancer. In each subgroup of nonsmall cell lung cancer, p53 abnormal status was shown to be associated with a poorer survival prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“However, not all mutated proteins lose their physiological function and in the case of p53, the disturbance of the regulation of the cell cycle depends on the site of the mutation [101, 102 ].”
BackgroundLanguage bias in randomised controlled trials published in English and German
Egger, M., Zellweger-Zähner, T., Schneider, M., Junker, C., Lengeler, C., & Antes, G. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02419-7 · Cited by 1,028
Meta-analysis of the literature or of individual patient data: is there a difference?
Stewart, L. A., & Parmar, M. K. B. (1993) · The Lancet · doi:10.1016/0140-6736(93)93004-k · Cited by 769
Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections
Cattoretti, G., Pileri, S., Parravicini, C., Becker, M. H. G., Poggi, S., Bifulco, C., Key, G., D'Amato, L., Sabattini, E., Feudale, E., et al. (1993) · The Journal of Pathology · doi:10.1002/path.1711710205 · Cited by 721
High levels of p53 protein in UV-irradiated normal human skin.
Hall, P. A., Ph, M., Hd, M., Dover, R., & Lane, D. P. (1993) · PubMed · Cited by 673
An immunochemical analysis of the human nuclear phosphoprotein p53
Vojtěšek, B., Bártek, J., Midgley, C. A., & Lane, D. P. (1992) · Journal of Immunological Methods · doi:10.1016/0022-1759(92)90122-a · Cited by 531
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.9.763 · Cited by 496
The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis
Levine, A., Perry, M., Chang, A., Silver, A., Dittmer, D., Wu, M., & Welsh, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.76 · Cited by 422
Paesmans, M., Sculier, J. P., Libert, P., Bureau, G., Dabouis, G., Thiriaux, J., Michel, J., Van Cutsem, O., Sergysels, R., & Mommen, P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1221 · Cited by 386
Self-citationAccumulation of p53 protein correlates with a poor prognosis in human lung cancer.
Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., & Doshi, H. M. (1992) · PubMed · Cited by 383
堀尾, 芳. (1995) · Medical Entomology and Zoology · doi:10.11501/3102283 · Cited by 352
Large Trials vs Meta-analysis of Smaller Trials: How Do Their Results Compare?
Cappelleri, J. C. (1996) · JAMA · doi:10.1001/jama.1996.03540160054033 · Cited by 336
Immunocytochemical markers in stage I lung cancer: relevance to prognosis.
Pastorino, U., Andreola, S., Tagliabue, E., Pezzella, F., Incarbone, M., Sozzi, G., Buyse, M., Menard, S., Pierotti, M., & Rilke, F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2858 · Cited by 302
Harpole, D. H., Herndon, J. E., Wolfe, W. G., Iglehart, J. D., & Marks, J. R. (1995) · PubMed · Cited by 290
O'Byrne, K. J., Koukourakis, M. I., Giatromanolaki, A., Cox, G., Turley, H., Steward, W. P., Gatter, K., & Langrish, V (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1129 · Cited by 275
Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaı̂tre, F., Meert, A. P., Vermylen, P., & Sculier, J. P. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)00127-6 · Cited by 270
Self-citationApoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
Brambilla, E. M., NEGOESCU, A., Gazzéri, S., Lantuéjoul, S., Moro‐Sibilot, D., Brambilla, C., & Coll, J. (1996) · Europe PMC (PubMed Central) · Cited by 268
D'Amico, M., Massey, M., Herndon II, P., Moore, M.-B., & Harpole, D. H. (1999) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(99)70294-1 · Cited by 233
P53 tumor suppressor gene therapy for cancer.
Nielsen, L. L., & Maneval, D. C. (1998) · PubMed · Cited by 232
Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi, R., & Shirakusa, T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.24.2018 · Cited by 211
Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer
Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Angeletti, C., Basolo, F., & Bevilacqua, G. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.193 · Cited by 200
Levels of p53 protein increase with maturation in human hematopoietic cells.
Kastan, M. B., Radin, A. I., Kuerbitz, S. J., Onyekwere, O. C., Wolkow, C., Civin, C. I., Stone, K. D., Woo, T. Y., Ravindranath, Y., & Craig, R. W. (1991) · PubMed · Cited by 188
Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Herndon, J. E., Shieh, D. B., Richards, W., Blanco, R., Xu, H. J., Strauss, G. M., & Sugarbaker, D. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2468 · Cited by 178
Ferreira, C. G., Tolis, C., & Giaccone, G. (1999) · Annals of Oncology · doi:10.1023/a:1008361818480 · Cited by 174
PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER
GIATROMANOLAKI, A., KOUKOURAKIS, M., O'BYRNE, K., FOX, S., WHITEHOUSE, R., TALBOT, D. C., HARRIS, A. L., & GATTER, K. C. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199605)179:1<80::aid-path547>3.0.co;2-x · Cited by 169
Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.
Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., Hittelman, W. N., & Hong, W. K. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1893 · Cited by 163
Apolinario, R. M., van der Valk, P., de Jong, J. S., Deville, W., van Ark-Otte, J., Dingemans, A. M., van Mourik, J. C., Postmus, P. E., Pinedo, H. M., & Giaccone, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2456 · Cited by 161
Przygodzki, R. M., Finkelstein, S. D., Langer, J., SWALSKY, P., Fishback, N. F., Bakker, A., Guinee, D. G., Koss, M., & Travis, W. D. (1996) · PubMed · Cited by 159
Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma
Eerola, A. (1996) · Lung Cancer · doi:10.1016/0169-5002(96)87803-2 · Cited by 150
The relationship of p53 immunostaining to survival in carcinoma of the lung
McLaren, R. S., Kuzu, I., Dunnill, M. S., Harris, A. L., Lane, D. P., & Gatter, K. C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.348 · Cited by 146
Fukuyama, Y., Mitsudomi, T., Sugio, K., Ishida, T., Akazawa, K., & Sugimachi, K. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.194 · Cited by 145
Ebina, M., Steinberg, S. M., Mulshine, J. L., & Linnoila, R. I. (1994) · PubMed · Cited by 135
Angiogenesis and molecular biologic substaging in patients with stage I non—small cell lung cancer
Harpole, D. H., Richards, W. G., Herndon, J. E., & Sugarbaker, D. J. (1996) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(96)00104-x · Cited by 128
Carbone, D. P., Mitsudomi, T., Chiba, I., Piantadosi, S., Rusch, V. W., Nowak, J. A., McIntire, D. D., Slamon, D. J., Gazdar, A. F., & Minna, J. D. (1994) · CHEST Journal · doi:10.1378/chest.106.6_supplement.377s · Cited by 113
Geradts, J., Fong, K. M., Zimmerman, P. V., Maynard, R. D., & Minna, J. D. (1999) · PubMed · Cited by 107
Do Molecular Markers Predict Survival in Non–Small-Cell Lung Cancer?
Greatens, T. M., Niehans, G. A., Rubins, J. B., Jessurun, J., Kratzke, R. A., Maddaus, M. A., & Niewoehner, D. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707108 · Cited by 104
Immunohistochemical study of p53 in human lung carcinomas.
Brambilla, E. M., Gazzéri, S., Moro‐Sibilot, D., de Fromentel, C. C., Gouyer, V., Jacrot, M., & Brambilla, C. (1993) · PubMed Central · Cited by 102
Ishida, H., Irie, K., Itoh, T., Furukawa, T., & Tokunaga, O. (1997) · Cancer · Cited by 101
Fontanini, G., Boldrini, L., Vignati, S., Chinè, S., Basolo, F., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C. A., & Bevilacqua, G. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10145-9 · Cited by 100
Maintenance chemotherapy for small cell lung cancer: a critical review of the literature
Sculier, J. P., Berghmans, T., Castaigne, C., Luce, S., Sotiriou, C., Vermylen, P., & Paesmans, M. (1998) · Lung Cancer · doi:10.1016/s0169-5002(97)00084-6 · Cited by 92
Self-citationDosaka‐Akita, H., Hu, S., Fujino, M., Harada, M., Kinoshita, I., Xu, H., Kuzumaki, N., Kawakami, Y., & Benedict, W. F. (1997) · PubMed · Cited by 91
Tomizawa, Y., Kohno, T., Fujita, T., Kiyama, M., Saito, R., Noguchi, M., Matsuno, Y., Hirohashi, S., Yamaguchi, N., Nakajima, T., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202384 · Cited by 89
p53 tumor suppressor gene therapy for cancer.
Roth, J. A., Swisher, S. G., & Meyn, R. E. (1999) · PubMed · Cited by 86
Angiogenesis: An indicator of metastasis in non-small cell lung cancer invading the thoracic inlet
Macchiarini, P., Fontanini, G., Dulmet, É., de Montpréville, V., Chapelier, A. R., Cerrina, J., Ladurie, F. L. R., & Dartevelle, P. (1994) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(94)90117-1 · Cited by 85
Top, B., Mooi, W. J., Klaver, S. G., Boerrigter, L., Wisman, P., Elbers, H. R. J., Visser, S., & Rodenhuis, S. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640203 · Cited by 79
Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., & Miyake, M. (1998) · Oncogene · doi:10.1038/sj.onc.1201776 · Cited by 79
bcl-2 and p53 protein expression in non-small cell lung cancers: Correlation with survival time
Ohsaki, Y., Toyoshima, E., Fujiuchi, S., Matsui, H., Hirata, S., Miyokawa, N., Kubo, Y., & Kikuchi, K. (1996) · Lung Cancer · doi:10.1016/s0169-5002(97)89521-9 · Cited by 73
Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., Kinoshita, M., Hadama, T., & Miyake, M. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.3.553 · Cited by 72
p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer
Vega, F., Iniesta, P., Caldés, T., Sánchez, A., López, J., de Juan, C., Díaz‐Rubio, E., Torres, A., Jl, B., & Benito, M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.334 · Cited by 70
p53 from basic research to clinical applications.
Tominaga, O., Hamelin, R., Remvikos, Y., Salmon, R. J., & Thomas, G. D. (1992) · PubMed · Cited by 65
A novel molecular staging protocol for non-small cell lung cancer
Miyake, M., Adachi, M., Huang, C., Higashiyama, M., Kodama, K., & Taki, T. (1999) · Oncogene · doi:10.1038/sj.onc.1202556 · Cited by 60
Lohmann, D. R., Pütz, B., Reich, U., Böhm, J., Präuer, H. W., & Höfler, H. (1994) · Lung Cancer · doi:10.1016/0169-5002(94)90601-7 · Cited by 56
Kawasaki, M., Nakanishi, Y., Kuwano, K., Yatsunami, J., Takayama, K., & Hara, N. (1997) · PubMed · Cited by 55
Kondo, K., Tsuzuki, H., Sasa, M., Sumitomo, M., Uyama, T., & Monden, Y. (1996) · Journal of Surgical Oncology · Cited by 54
Dalquen, P., Sauter, G., Torhorst, J. K. H., Schultheiss, E., Jordan, P., LEHMANN, S., SOLÈR, M., Stulz, P. M., Mihatsch, M. J., & Gudat, F. G. (1996) · The Journal of Pathology · Cited by 48
Molecular and biological factors in the prognosis of non-small cell lung cancer
Kanters, S., Lammers, J. J., & Voest, E. E. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081389 · Cited by 45
Bergqvist, M., Brattström, D., Larsson, A., Holmertz, J., Hesselius, P., Rosenberg, L., Wagenius, G., & Brodin, O. (1998) · PubMed · Cited by 35
Prognostic Biomarker Study in Pathologically Staged N1 Non-Small Cell Lung Cancer
Komaki, R. U., Milas, L., Ro, J. Y., Fujii, T., Perkins, P., Allen, P. K., Sikes, C. R., Mountain, C. F., & Ordóǹez, N. G. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00898-5 · Cited by 33
Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Chinè, S., Angeletti, C. A., & Bevilacqua, G. (1996) · PubMed · Cited by 30
Tanaka, F., Yanagihara, K., Ohtake, Y., MIYAHARA, R., 河野洋三, Fukuse, T., Hitomï, S., & Wada, H. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00766.x · Cited by 25
Meert, A., Berghmans, T., Branle, F., Lemaître, F., Mascaux, C., Rubesova, E., Vermylen, P., Paesmans, M., & Sculier, J. (1999) · PubMed · Cited by 22
Self-citationLuce, S., Paesmans, M., Berghmans, T., Castaigne, C., Sotiriou, C. P., Vermylen, P., & Sculier, J. (1998) · PubMed · Cited by 20
Self-citationExpression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation
(1993) · Lung Cancer · doi:10.1016/0169-5002(93)90516-z · Cited by 2
Cited by
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Self-citationSystematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Evaluation of the Quality of Prognosis Studies in Systematic Reviews
Hayden, J. A., Côté, P., & Bombardier, C. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200603210-00010 · Cited by 1,452
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001216 · Cited by 1,013
Ki67 is a promising molecular target in the diagnosis of cancer (Review)
LI, L. T., JIANG, G., CHEN, Q., & ZHENG, J. N. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2914 · Cited by 859
Metadata
- Authors
- Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaitre, F., Mascaux, C., Meert, A. P., Vallot, F., Lafitte, J. J., & Sculier, J. P.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2001-10
- Volume
- 18
- Issue
- 4
- Pages
- 705-719
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2030196526
- Cited by
- 418
- References
- 68
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.